NCT01698931 - Efficacy of Repaglinide in Subjects With Type 2 Diabetes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 26, 2002

Primary Completion Date

March 6, 2003

Study Completion Date

March 6, 2003

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

DRUG

repaglinide

1 mg before each main meal on three separate dosing visits separated by a wash-out period

DRUG

glyburide

5 mg before breakfast and before supper on three separate dosing visits separated by a wash-out period

DRUG

placebo

Before each main meal on three separate dosing visits separated by a wash-out period

Trial Locations (1)

Novo Nordisk Investigational Site, Padua